Authors
Issameddine Ajmi, Mathis Philipp Frings, Mathias Forkmann, Christian Mahnkopf
Published in
Expert review of cardiovascular therapy. Oct 09, 2026. Epub Oct 09, 2026.
Abstract
Guidelines advise deferring primary-prevention implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) implantation until left ventricular ejection fraction (LVEF) is reassessed after at least three months of medical therapy in heart failure with reduced ejection fraction (HFrEF). Real-world data under contemporary quadruple therapy are limited.
Retrospective single-center cohort of 65 HFrEF patients (Coburg Hospital, Germany; October 2023-December 2024), prescribed beta-blocker, angiotensin receptor-neprilysin inhibitor, mineralocorticoid receptor antagonist and SGLT2 inhibitor (all four in 92%; doses not recorded). LVEF was measured by echocardiography (TTE) and cardiac magnetic resonance (CMR) at baseline and ~3 months; reader blinding was not documented. Device implantation followed guideline criteria. Patients with severe arrhythmic events were excluded.
Twenty-nine patients (44.6%) received a device. LVEF rose on TTE (28.0→36.0%) and CMR (26.3→38.5%) (both p < 0.001), mainly without device implantation (TTE +13.0 vs + 1.5 points). Larger baseline left ventricular end-diastolic diameter was associated with smaller recovery (β = -0.41, p = 0.006) and device implantation (odds ratio 1.11/mm, 95% CI 1.01-1.22). Adverse events were not recorded.
LVEF recovery was common, and associations are consistent with disease severity. Findings are hypothesis-generating; absent dose, arrhythmic-outcome and wearable-defibrillator data and the selected cohort limit generalizability.
PMID:
42855941
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0